The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control.

Published

Journal Article (Review)

PURPOSE OF REVIEW: Diabetes mellitus is an exploding epidemic costing billions of dollars yearly. Type 2 diabetes mellitus is characterized by insulin resistance and is closely associated with arterial hypertension. Emerging literature has demonstrated that modulation of the renin-angiotensin-aldosterone system by use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers leads to improved insulin sensitivity, glycemic control and possibly prevention of type 2 diabetes mellitus. RECENT FINDINGS: Several major studies investigating angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use in either hypertensive or heart failure patients have found lower incidence of type 2 diabetes mellitus when compared with placebo, beta-blocker, calcium-channel blocker or diuretic. None of these trials, however, studied prevention of diabetes as a primary endpoint. The Dream Trial and upcoming NAVIGATOR, ONTARGET/TRANSCEND trials specifically look at the prevention of diabetes as a primary endpoint. Several studies have evaluated possible mechanisms of how the renin-angiotensin-aldosterone system can alter insulin sensitivity and glycemic control. SUMMARY: This review will focus on the recent literature that demonstrates renin-angiotensin-aldosterone system modulation and its effects on diabetes prevention, glycemic control and insulin sensitivity, as well as possible mechanisms for achieving this goal.

Full Text

Duke Authors

Cited Authors

  • Perkins, JM; Davis, SN

Published Date

  • April 2008

Published In

Volume / Issue

  • 15 / 2

Start / End Page

  • 147 - 152

PubMed ID

  • 18316950

Pubmed Central ID

  • 18316950

Electronic International Standard Serial Number (EISSN)

  • 1752-2978

Digital Object Identifier (DOI)

  • 10.1097/MED.0b013e3282f7026f

Language

  • eng

Conference Location

  • England